Key Highlights
- Scinai Immunotherapeutics shares closed up 47% at $2.44.
- The company terminated its PC111 option and license agreement with PinCell following a denied extension request.
- Scinai is redirecting R&D efforts toward its NanoAb pipeline and IL-17 candidates.
- The company's CDMO operations held roughly $3.1 million in contracted customer orders as of August 16, with projected 2026 CDMO sales of about $5 million.
Scinai Immunotherapeutics Ltd. (NASDAQ: SCNI) shares closed up 47% at $2.44 after the company terminated its PC111 option and license agreement with PinCell following a denied extension request.
What Happened
The move redirects R&D efforts toward Scinai's NanoAb pipeline and IL-17 candidates to conserve Capital for its expanding CDMO operations, which held roughly $3.1 million in contracted customer orders as of August 16 while projecting around $5 million in 2026 CDMO sales.
Market Reaction
Shares surged sharply as investors responded to the capital conservation move and the sharper strategic focus on the NanoAb pipeline, IL-17 candidates, and the growing CDMO business.
Outlook
Continued growth of Scinai's CDMO operations, alongside progress on its NanoAb pipeline and IL-17 candidates, represents the next relevant developments for the company following the PC111 termination.
FAQs
Q: Why did Scinai Immunotherapeutics shares surge 47%?
A: Shares surged after the company terminated its PC111 license agreement with PinCell, redirecting focus and capital toward its NanoAb pipeline, IL-17 candidates, and CDMO operations.
Q: Why was the PC111 agreement terminated?
A: Following a denied extension request from PinCell.
Q: What are Scinai's CDMO sales projections for 2026?
A: Approximately $5 million, with about $3.1 million in contracted customer orders as of August 16.
Download Free Report – Explore 3 Stock Ideas & Industry Insights
Unlock 3 stock ideas and key industry insights in our free report. This information is general in nature and does not consider your personal objectives, financial situation, or needs. It is not financial advice.
All investments involve risk—consider independent advice before making any investment decisions.
View 3 Research Reports
Disclaimer:
Kalkine Equities LLC, with Delaware File Number 4697384, Foreign Qualification Registration in California File Number 202109211078, and Texas File Number 805521396, is authorized to provide general advice only. The information on https://kalkine.com/ does not take into account any of your investment objectives, financial situation or needs. You should consider the appropriateness of advice taking into account your own objectives, financial situation and needs and seek independent financial advice before making any financial decisions. The link to our Terms and Conditions and Privacy Policy has been provided for your reference. On the date of publishing the reports (mentioned on the website), employees and/or associates of Kalkine do not hold positions in any of the stocks covered on the website. These stocks can change any time and readers of the reports should not consider these stocks as advice or recommendations later.